1.28
+1.59%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Neptunus Bioengineering Co
Its shares trade on Shenzhen under the ticker 000078.SZ. It has been listed since 18 December 1998. In the fiscal year to 31 December 2025, it reported revenue of CN¥26.67bn and a net loss of CN¥563.1m. At that date it held total assets of CN¥26.33bn and shareholders' equity of CN¥1.23bn.
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the business of pharmaceutical industry. The company is headquartered in Shenzhen, Guangdong. The Company’s main products include anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products and other pharmaceuticals, as well as healthcare products, health food and medical instrument. The firm distributes its products mainly in domestic market, with East China as its main market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 18 Dec 1998
- Employees
- 9,874
- Website
- neptunusbio.com ↗
Leadership
Pay as last reported
- Mr. Simin ZhangChairman of the Board, since 1992CN¥150,000
- Mr. Feng ZhangPresident, Vice Chairman of the Board, since 2001CN¥4.2m
- Mr. Dakai ShenChief Financial Officer, Vice President, Director, since 2006CN¥2.0m
- Mr. Yifei ZhangExecutive Vice President, Director, since 2010CN¥2.1m
- Mr. Yunlei WangVice President, Secretary of the BoardCN¥751,100
- Mr. Rui JinVice President, Director, since 2021CN¥1.4m
- Mr. Ge JinVice PresidentCN¥751,100
- Mr. Xiaoming ShiVice PresidentCN¥1.1m
- Mr. Shuancheng YangVice PresidentCN¥1.2m
- Mr. Xiaopeng ZhangVice PresidentCN¥1.2m
- Mr. Hanshu CheDirectorCN¥150,000
- Mr. Huanjun WangIndependent DirectorCN¥150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 17
- Environment
- 26
- Social
- 5
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Neptunus Bioengineering employs 9,874 full-time employees in the Health Care sector.
- The company's main products include anti-tumor and cardiovascular drugs in the domestic market.
- East China serves as the primary market for Shenzhen Neptunus Bioengineering's pharmaceutical distribution.
Weaknesses
- Shenzhen Neptunus Bioengineering focuses solely on the domestic market without international expansion.
- The company's product range lacks diversity beyond pharmaceuticals and healthcare products.
- No mention of international market presence or global distribution channels for Neptunus Bioengineering.
Opportunities
- Expanding into international markets could leverage Shenzhen Neptunus Bioengineering's existing product portfolio.
- Growing demand for marine drugs and respiratory drugs presents new market opportunities.
- Increasing healthcare spending in East China supports further market penetration for Neptunus.
Threats
- Overreliance on the domestic market exposes Shenzhen Neptunus Bioengineering to local economic fluctuations.
- Competition from other domestic pharmaceutical companies in East China is a potential threat.
- Lack of international presence may limit growth opportunities in global health care markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.